BITT-CD4F10

N/A

Report date: 2025/01/26 18:45:41

Base Information

Drug NameBITT-CD4F10
Drug Alias NameCD40 antagonist (Boston Immune Technologies and Therapeutics)BITT-CD4F10
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionTumor necrosis factor receptor superfamily member 5 inhibitors
TargetsTumor necrosis factor receptor superfamily member 5
Therapy Area/IndicationsInflammationAutoimmune DiseasesPsoriasis +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesBoston Immune Technologies & Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesBoston Immune Technologies & Therapeutics
Inactive CompaniesN/A
Active IndicationsInflammationAutoimmune DiseasesPsoriasis +[9] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A